Science / Technology

Vaxxel R&D program to address the global need in vaccine against pneumoviruses is based on two proprietary technologies :

metavac-white

Metavac® Vaccine platform

From its expertise in virology, Vaxxel developed a proprietary live-attenuated viral platform based on an engineered recombinant HMPV strain. This proprietary Metavac® platform is versatile by modifying its genome in order to express additional viral antigens of interest, such as the F antigen of HRSV.

bioreacteur-1-white

Bioproduction platform

Vaxxel acquired from Transgene the DuckCelt®-T17 avian cell line, permissive to several viruses, including pneumoviruses and producing high yields of Metavac®-based vaccine candidates, while preserving its immunogenic properties. This cell line growing in suspension and serum-free conditions presents suitable characteristics for industrial scalable production in bioreactor.

Scientific publications

Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development.

Dubois J, Pizzorno A, Cavanagh M-H, Padey B, Nicolas de Lamballerie C, Uyar O, Venable M-C, Carbonneau J, Traversier A, Julien T, Lavigne S, Couture C, Lina B, Hamelin M-E, Terrier O, Rosa-Calatrava M, Boivin G. Vaccines 2019, 7(4), 164.

https://www.mdpi.com/2076-393X/7/4/164

Human Metapneumovirus Activates NOD-like Receptor Protein 3 Inflammasome via Its Small Hydrophobic Protein Which Plays a Detrimental Role during Infection in Mice.

Lê V.B, Dubois J, Couture C, Cavanagh M-H, Uyar O, Pizzorno A, Rosa-Calatrava M, Hamelin M-E, Boivin G. PLoS Pathog. — April 2019

https://pubmed.ncbi.nlm.nih.gov/30964929/

Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.

Emma Petiot, Anaïs Proust, Aurélien Traversier, Laurent Durous, Frédéric Dappozze, Marianne Gras, Chantal Guillard, Jean-Marc Balloul, Manuel Rosa-Calatrava. Vaccine. — May 2018

https://pubmed.ncbi.nlm.nih.gov/28571695/

Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia.

Dubois J, Cavanagh M-H, Terrier O, Hamelin M-E, Lina B, Shi R, Rosa-Calatrava M, Boivin G. J Gen Virol. — June 2017

https://pubmed.ncbi.nlm.nih.gov/28613142/

Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model.

Aerts L, Cavanagh MH, Dubois J, Carbonneau J, Rhéaume C, Lavigne S, Couture C, Hamelin MÈ, Boivin G. PLoS One. — March 2015

https://pubmed.ncbi.nlm.nih.gov/25803584/

Recent developments with live-attenuated recombinant paramyxovirus vaccines.

Jean-Christophe Le Bayon, Bruno Lina, Manuel Rosa-Calatrava, Guy Boivin. Rev Med Virol. — January 2013

https://pubmed.ncbi.nlm.nih.gov/22570186/

Ten years of human metapneumovirus research.

F Feuillet, B Lina, M Rosa-Calatrava, G Boivin. J Clin Virol . — February 2012

https://pubmed.ncbi.nlm.nih.gov/22074934/

greenlogo4

Vaxxel SAS

43, Boulevard du 11 Novembre 1918,

L’Atrium | 69100 Villeurbanne | France

Get in touch

contact@vaxxel.fr

Follow us